Medscape is available in 5 Language Editions – Choose your Edition here.


CNS Whipple Disease Clinical Presentation

  • Author: George C Bobustuc, MD; Chief Editor: Niranjan N Singh, MD, DM  more...
Updated: Dec 11, 2014


Whipple disease commonly starts with GI complaints, but because of the multisystemic involvement, presentation can be quite variable. At any time in the course of the disease a constellation of symptoms relating to different organ systems may be present. The GI symptomatology is initially mild, and affected persons may go years before seeking medical attention, often for symptoms other than GI-related ones.

  • Symptoms at presentation (other than CNS related) include the following:
    • Weight loss (80-100% of patients) generally ranges from 20-40 pounds over several months to years.
    • Diarrhea, watery or fatty, occurs in 75% of patients. Occult blood loss was reported with almost all patients, but clinically relevant lower GI bleed (hematochezia or melena) is distinctly unusual.
    • Arthralgia (70% of patients) typically is the most common cause of initial concern for the patient. It is migratory in nature and involves large joints in an asymmetric fashion.
    • Abdominal (nonspecific) pain (50%) is usually more severe after eating.
    • Chest (ie, pleural and/or pericardial) pain with or without nonproductive cough occurs in 50% of patients.
    • Fever occurs in 45% of patients.
    • Leg swelling (25%) typically occurs after 1-2 years of progressive arthralgias and diarrhea.
    • Glossitis occurs in 20% of patients.
    • Abdominal fullness (ie, ascites and/or splenomegaly) occurs in 20% of patients.
  • Fewer than 10-15% of patients with Whipple disease eventually develop clinically significant CNS involvement. A review of patients with CNS-WD showed that by the time of CNS disease onset they often report previous systemic problems, including the following:
    • Chronic migratory arthralgias or polyarthralgias, sometimes for several years, preceding the onset of neurological symptoms (48% of patients)
    • Unexplained weight loss (46% of patients)
    • GI complaints (45% of patients), including chronic diarrhea in 39%, abdominal pain in 20%, steatorrhea in 13%, and abdominal distension in 8%
    • Fever of unknown origin (40%)
    • Malaise (29%)
    • Night sweats (4%)
    • Blurry vision (2%)
  • GI complaints usually precede CNS-WD symptoms by several years. A limited group of patients has manifestations other than GI at onset, and they seem to have a higher likelihood of developing CNS involvement. CNS symptoms are more frequent at the time of relapse (60-70% of relapse patients, most of whom do not have recurrence of intestinal symptoms).
  • CNS symptoms: Fewer than 100 cases of patients with confirmed CNS-WD have been reported. Most of these patients presented for a combination of neurological and psychiatric symptoms. Most commonly the symptoms included cognitive changes, movement disorders (eg, myoclonus), hypothalamus-related problems (eg, polydipsia, hyperphagia, decreased libido), and seizures.
  • Altered mentation was the most frequent presenting symptom, seen in almost 75% of patients with CNS-WD.
    • Almost 50% of these patients had a concomitant psychiatric illness (eg, depression, hypomania, anxiety, psychosis; mostly with delusional content, or change in personality).
    • Two thirds of patients with altered mentation (almost 50% of all patients with CNS-WD) had dementia.
    • Other mentation problems were limited loss of memory, change in reasoning, and change in attention span.[17]
  • Hypothalamus-related problems (eg, polydipsia, hyperphagia, decreased libido, amenorrhea, change in sleep-wake cycle with insomnia, but never with isolated somnolence), though clinically significant and largely disregarded by patients, represented initial manifestations of CNS involvement in 30% of patients.
  • Myoclonus, including brief, irregular, jerky movements, represented the presenting symptom in 10-15% of patients.
  • Seizures (ie, simple or complex partial seizures, generalized tonic-clonic seizures, either alone or complicating partial seizures) represented the presenting symptom in about 10-15% of patients.
  • A specific clinical triad noted in CNS-WD includes dementia, vertical ophthalmoplegia, and myoclonus.


Exhaustive physical examination should be performed to assess the extent of extraneuraxial involvement; systems and/or organs usually known to be affected in Whipple disease (ie, GI, cardiovascular, pulmonary, CNS, liver, skin) should be targeted.

  • Signs (other than CNS) seen at presentation are as follows:
    • Hypotension (defined as systolic blood pressure < 110 mm Hg and diastolic blood pressure < 60 mm Hg): This is usually a very late finding and has been described in more than 70% of patients with long-standing GI complaints (usually for several years). In some patients, hypotension is part of their dysautonomia. Another dysautonomic feature described in the late stages of Whipple disease is hypothermia.
    • Peripheral lymphadenopathy (more than 50% of patients)
    • Nonspecific abdominal tenderness (50% of patients)
    • Hyperpigmentation and/or skin photosensitivity (40% of patients; does not represent adrenal failure)
    • Low-grade fever (40% of patients)
    • Cardiac murmurs (more than 30% of patients)
    • Peripheral edema (25% of patients)
    • Splenomegaly (25% of patients)
    • Glossitis (25% of patients)
    • Ill-defined abdominal mass (20% of patients)
    • Pleural and pericardial friction rubs (less than 10% of patients)
    • Ascites (very infrequently chylous): This is rare.
    • Uveitis (2% of patients)
  • In patients with a high likelihood of having Whipple disease (based on historical data and general examination), the comprehensive neurologic examination should target cognition and (eye) movement abnormalities, especially signs with high pathognomonic value (eg, vertical supranuclear ophthalmoplegia [SNO] with or without oculomasticatory myorhythmia [OMM][18] and/or oculofacialskeletal myorhythmia [OFSM]).
  • Although dementia, ophthalmoplegia, and myoclonus represent a highly specific diagnostic triad, it is encountered in only approximately 10% of patients with CNS-WD.
    • Dementia - Present in more than 50% of patients with CNS-WD
    • Psychiatric illness (ie, depression; hypomania; anxiety; psychosis, mostly with delusional content; change in personality) - Present in almost 50% of patients
    • Ophthalmoplegia - Present in 50% of patients
    • Myoclonus - Present in 20% of patients
  • Eye findings in CNS-WD are as follows:
    • Supranuclear ophthalmoplegia
      • Both horizontal and vertical SNO are found in approximately two thirds of patients with SNO.
      • Pure vertical SNO is found in approximately one third of patients with SNO.
      • Pure horizontal SNO is never found in CNS-WD.
    • OMM and OFSM are synchronous movements combining pendular vergence oscillations (PVOs) with myorhythmia.
      • PVOs are characterized by 1-Hz, rhythmic, smooth, continuous, convergent eye movements (unilateral or bilateral), varying from 1-25 degrees of amplitude per eye. Return divergent movements never go beyond the primary position. The oscillations continue during sleep and may be subtle and asymmetric. Convergent and return divergent movements happen at the same speed (this does not represent nystagmus, as both phases are of the same speed) and are not accompanied by miosis or accommodation.
      • Myorhythmia represents regular, repetitive contractions (1-2 Hz) of the facial, masticatory, and pharyngeal muscles with or without limb involvement. It persists through sleep and should be distinguished from oculopalatal myoclonus, which most commonly is caused by brainstem strokes and demyelination with a similar average frequency, although it is slightly irregular.
      • PVOs are synchronous with myorhythmic movements of the masticatory muscles and in some patients may include facial and pharyngeal muscles (in the case of OMM) and more extensive myorhythmic movements involving facial and limb muscles (in the case of OFSM).
      • OMM and OFSM are very infrequent signs (< 20 cases have been reported in the literature), and they have been described only in CNS-WD. In all reported cases, OMM and OFSM always have been associated with vertical SNO. Although OMM and OFSM are highly specific for CNS-WD, they have a very low sensitivity of approximately 20%.
      • OMM/OFSM together with vertical SNO are highly pathognomonic for CNS-WD and should prompt timely diagnosis and treatment.
    • Isolated ptosis is found in 23% of patients.
    • Pupillary abnormalities (usually anisocoria or unreactive pupil) are found in only 18% of patients.
  • Other neurologic signs are as follows:
    • Hypothalamic manifestations (in 30% of patients) included polydipsia, hyperphagia, decreased libido, amenorrhea, changes in sleep-wake cycle, and disruptive insomnia. Somnolence as an isolated symptom has never been encountered. Hypothalamus-driven hypopituitarism as a presenting feature was reported in one patient with Whipple disease at relapse, with an MRI-proven rostral infundibular lesion and low levels of cortisol, free testosterone, and free thyroxine without an elevated thyroid-stimulating hormone.[19]
    • Ataxia (cerebellar) is found in 25% of patients.
    • Seizures are found in 25% of patients (ie, simple or complex partial seizures, generalized tonic-clonic seizures, either alone or complicating partial seizures).
    • Segmental myoclonus (which is irregular/nonrhythmic, to be distinguished from myorhythmic movements of OMM and OFSM) is found in 20% of patients.
    • Sensory deficits (usually in a central distribution) are found in 10% of patients.
    • Isolated cranial nerve (CN) palsy (CN III, IV, V, VI, or VII) is very rare (< 3% of patients).


Whether the clinical manifestations of Whipple disease result from direct bacterial invasion or from the ensuing inflammatory response is not yet clear.

More effective (ie, sensitive) diagnostic techniques (eg, PCR) have continued to provide more and more evidence of direct bacterial invasion at the various symptomatic-target organ sites, suggesting a combined mechanism of bacterial invasion and ensuing inflammatory response.

Contributor Information and Disclosures

George C Bobustuc, MD Consulting Staff, Department of Neuro-oncology, MD Anderson Cancer Center of Orlando

George C Bobustuc, MD is a member of the following medical societies: American Academy of Neurology, Texas Medical Association, Society for Neuro-Oncology, American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Florian P Thomas, MD, PhD, Drmed, MA, MS Director, National MS Society Multiple Sclerosis Center; Professor and Director, Clinical Research Unit, Department of Neurology, Adjunct Professor of Physical Therapy, Associate Professor, Institute for Molecular Virology, St Louis University School of Medicine; Editor-in-Chief, Journal of Spinal Cord Medicine

Florian P Thomas, MD, PhD, Drmed, MA, MS is a member of the following medical societies: Academy of Spinal Cord Injury Professionals, American Academy of Neurology, American Neurological Association, Consortium of Multiple Sclerosis Centers, National Multiple Sclerosis Society, Sigma Xi

Disclosure: Nothing to disclose.

Chief Editor

Niranjan N Singh, MD, DM Associate Professor of Neurology, University of Missouri-Columbia School of Medicine

Niranjan N Singh, MD, DM is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Headache Society

Disclosure: Nothing to disclose.

Additional Contributors

Norman C Reynolds, Jr, MD Neurologist, Veterans Affairs Medical Center of Milwaukee; Clinical Professor, Medical College of Wisconsin

Norman C Reynolds, Jr, MD is a member of the following medical societies: American Academy of Neurology, Association of Military Surgeons of the US, International Parkinson and Movement Disorder Society, Sigma Xi, Society for Neuroscience

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Mark Gilbert, MD to the development and writing of this article.

  1. Compain C, Sacre K, Puéchal X, Klein I, Vital-Durand D, Houeto JL, et al. Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. Medicine (Baltimore). 2013 Nov. 92(6):324-30. [Medline].

  2. Balasa M, Gelpi E, Rey MJ, Vila J, Ramió-Torrentà L, Quiles Granado AM, et al. Clinical and neuropathological variability in clinically isolated central nervous system Whipple's disease. Brain Pathol. 2014 Apr. 24(3):230-8. [Medline].

  3. Whipple GH. A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Johns Hopkins Hosp Bull. 1907. 18:382-391.

  4. Black-Schaffer B. The tinctorial demonstration of a glycoprotein in Whipple's disease. Proc Soc Exp Biol Med. 1949. 72:225.

  5. Paulley JW. A case of Whipple's disease (intestinal lipodystrophy). Gastroenterology. 1952. 22:128-33.

  6. Keinath RD, Merrell DE, Vlietstra R, Dobbins WO 3rd. Antibiotic treatment and relapse in Whipple's disease. Long-term follow-up of 88 patients. Gastroenterology. 1985 Jun. 88(6):1867-73. [Medline].

  7. Wilson KH, Blitchington R, Frothingham R, Wilson JA. Phylogeny of the Whipple's-disease-associated bacterium. Lancet. 1991 Aug 24. 338(8765):474-5. [Medline].

  8. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med. 1992 Jul 30. 327(5):293-301. [Medline].

  9. Ramzan NN, Loftus E, Burgart LJ, et al. Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med. 1997 Apr 1. 126(7):520-7. [Medline].

  10. Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, et al. Cultivation of the bacillus of Whipple's disease. N Engl J Med. 2000 Mar 2. 342(9):620-5. [Medline].

  11. Raoult D, Ogata H, Audic S. Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res. 2003 Aug. 13(8):1800-9. [Medline].

  12. Raoult D, Ogata H, Audic S, et al. Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res. 2003 Aug. 13(8):1800-9. [Medline].

  13. Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, et al. Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei. Lancet. 2003 Feb 22. 361(9358):637-44. [Medline].

  14. Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000 Dec. 11(4):321-33. [Medline].

  15. Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D. Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis. 2008 Sep 1. 47(5):659-67. [Medline].

  16. Bonhomme CJ, Renesto P, Nandi S, Lynn AM, Raoult D. Serological microarray for a paradoxical diagnostic of Whipple's disease. Eur J Clin Microbiol Infect Dis. 2008 Oct. 27(10):959-68. [Medline].

  17. Panegyres PK, Foster JK, Fallon M, Connor C. The amnesic syndrome of primary Whipple disease of the brain. Cogn Behav Neurol. 2010 Mar. 23(1):49-51. [Medline].

  18. Schwartz MA, Selhorst JB, Ochs AL, Beck RW, Campbell WW, Harris JK, et al. Oculomasticatory myorhythmia: a unique movement disorder occurring in Whipple's disease. Ann Neurol. 1986 Dec. 20(6):677-83. [Medline].

  19. Brandle M, Ammann P, Spinas GA, Dutly F, Galeazzi RL, Schmid C, et al. Relapsing Whipple's disease presenting with hypopituitarism. Clin Endocrinol (Oxf). 1999 Mar. 50(3):399-403. [Medline].

  20. von Herbay A, Ditton HJ, Schuhmacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. Gastroenterology. 1997 Aug. 113(2):434-41. [Medline].

  21. De Coene B, Gilliard C, Indekeu P, Duprez T, Trigaux JP. Whipple's disease confined to the central nervous system. Neuroradiology. 1996 May. 38(4):325-7. [Medline].

  22. Le Scanff J, Gaultier JB, Durand DV, Durieu I, Celard M, Benito Y, et al. [Tropheryma whipplei and Whipple disease: false positive PCR detections of Tropheryma whipplei in diagnostic samples are rare]. Rev Med Interne. 2008 Nov. 29(11):861-7. [Medline].

  23. Seneca V, Imperato A, Colella G, Cioffi V, Mariniello G, Gangemi M. Recurrent acute obstructive hydrocephalus as clinical onset of cerebral Whipple's disease. Clin Neurol Neurosurg. 2010 Oct. 112(8):717-21. [Medline].

  24. Adams M, Rhyner PA, Day J, DeArmond S, Smuckler EA. Whipple's disease confined to the central nervous system. Ann Neurol. 1987 Jan. 21(1):104-8. [Medline].

  25. Benito-León J, Sedano LF, Louis ED. Isolated central nervous system Whipple's disease causing reversible frontotemporal-like dementia. Clin Neurol Neurosurg. 2008 Jul. 110(7):747-9. [Medline].

  26. Clarke CE, Falope ZF, Abdelhadi HA, Franks AJ. Cervical myelopathy caused by Whipple's disease. Neurology. 1998 May. 50(5):1505-6. [Medline].

  27. Comer GM, Brandt LJ, Abissi CJ. Whipple's disease: a review. Am J Gastroenterol. 1983 Feb. 78(2):107-14. [Medline].

  28. Cooper GS, Blades EW, Remler BF, Salata RA, Bennert KW, Jacobs GH. Central nervous system Whipple's disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime. Gastroenterology. 1994 Mar. 106(3):782-6. [Medline].

  29. Dobbins WO 3rd. The diagnosis of Whipple's disease. N Engl J Med. 1995 Feb 9. 332(6):390-2. [Medline].

  30. Fenollar F, Birg ML, Gauduchon V. Culture of Tropheryma whipplei from human samples: a 3-year experience (1999 to 2002). J Clin Microbiol. 2003 Aug. 41(8):3816-22. [Medline].

  31. Fenollar F, Fournier PE, Robert C. Use of genome selected repeated sequences increases the sensitivity of PCR detection of Tropheryma whipplei. J Clin Microbiol. 2004 Jan. 42(1):401-3. [Medline].

  32. Knox DL, Green WR, Troncoso JC, Yardley JH, Hsu J, Zee DS. Cerebral ocular Whipple's disease: a 62-year odyssey from death to diagnosis. Neurology. 1995 Apr. 45(4):617-25. [Medline].

  33. Kowalczewska M, Villard C, Lafitte D, Fenollar F, Raoult D. Global proteomic pattern of Tropheryma whipplei: a Whipple's disease bacterium. Proteomics. 2009 Mar. 9(6):1593-616. [Medline].

  34. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol. 1996 Oct. 40(4):561-8. [Medline].

  35. Lynch T, Odel J, Fredericks DN, Louis ED, Forman S, Rotterdam H, et al. Polymerase chain reaction-based detection of Tropheryma whippelii in central nervous system Whipple's disease. Ann Neurol. 1997 Jul. 42(1):120-4. [Medline].

  36. Marth T, Neurath M, Cuccherini BA, Strober W. Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology. 1997 Aug. 113(2):442-8. [Medline].

  37. Marth T, Roux M, von Herbay A, Meuer SC, Feurle GE. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin Immunol Immunopathol. 1994 Aug. 72(2):217-26. [Medline].

  38. Masselot F, Boulos A, Maurin M. Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm. Antimicrob Agents Chemother. 2003 May. 47(5):1658-64. [Medline].

  39. Moos V, Kunkel D, Marth T, Feurle GE, LaScola B, Ignatius R, et al. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease. J Immunol. 2006 Aug 1. 177(3):2015-22. [Medline].

  40. Pollock S, Lewis PD, Kendall B. Whipple's disease confined to the nervous system. J Neurol Neurosurg Psychiatry. 1981 Dec. 44(12):1104-9. [Medline].

  41. Richardson DC, Burrows LL, Korithoski B, Salit IE, Butany J, David TE, et al. Tropheryma whippelii as a cause of afebrile culture-negative endocarditis: the evolving spectrum of Whipple's disease. J Infect. 2003 Aug. 47(2):170-3. [Medline].

  42. Ryser RJ, Locksley RM, Eng SC, Dobbins WO 3rd, Schoenknecht FD, Rubin CE. Reversal of dementia associated with Whipple's disease by trimethoprim-sulfamethoxazole, drugs that penetrate the blood-brain barrier. Gastroenterology. 1984 Apr. 86(4):745-52. [Medline].

  43. Sanavro SM, Voerman HJ. Whipple's disease: easily diagnosed, if considered. Neth J Med. 2009 Mar. 67(3):108. [Medline].

  44. Schneider T, Stallmach A, von Herbay A. Treatment of refractory Whipple disease with interferon-gamma. Ann Intern Med. 1998 Dec 1. 129(11):875-7. [Medline].

  45. Schnider P, Trattnig S, Kollegger H, et al. MR of cerebral Whipple disease. AJNR Am J Neuroradiol. 1995 Jun-Jul. 16(6):1328-9. [Medline].

  46. Sloan LM, Rosenblatt JE, Cockerill FR. Detection of Tropheryma whipplei DNA in clinical specimens by LightCycler real-time PCR. J Clin Microbiol. 2005 Jul. 43(7):3516-8. [Medline].

  47. Swartz MN. Whipple's disease--past, present, and future. N Engl J Med. 2000 Mar 2. 342(9):648-50. [Medline].

  48. Wilson KH. New vistas for bacteriologists: analysis based on 16S rRNA sequences provides a rapid and reliable approach to the identity of human pathogens. ASM News. 1992. 58:318-21.

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.